An AI-powered software designed for prostate most cancers detection, QP-Prostate by Quibim, has been chosen for rollout throughout seven NHS hospitals in England.
This two-year initiative, introduced on July 9, 2025, goals to boost early analysis of prostate most cancers, which is the most typical most cancers amongst males within the UK.
The QP-Prostate software program assists radiologists by robotically figuring out suspicious areas inside prostate MRI scans. Based on a Quibim press launch, early scientific information collected suggests the software can contribute to detecting a further 10.6% of early-stage prostate cancers. This aligns with the NHS Lengthy Time period Plan’s goal to extend early analysis charges to 75% by 2028.
Dr Ángel Alberich-Bayarri, CEO of Quibim, mentioned: “This NHS rollout is a significant milestone in our mission to enhance most cancers diagnostics by AI. We’re proud to assist the NHS in advancing early detection and addressing well being inequalities in prostate most cancers care. By empowering radiologists with AI, we might help guarantee extra males are identified earlier, when their probabilities of survival are highest.”
The challenge will contain over 3,000 sufferers and numerous areas, with the seven NHS hospitals not but introduced. Over the 2 years, the challenge will assess will increase in prostate most cancers diagnoses and early-stage detections, and the cost-effectiveness and long-term affect on NHS sources. Moreover, a key facet of the analysis is the potential of AI to deal with diagnostic disparities, notably for Black males who expertise a better threat and mortality fee from prostate most cancers. The rollout additionally plans to have interaction with the general public and sufferers to grasp their views on AI in healthcare and guarantee its moral deployment.
David Bazaga, VP of product at Quibim, added: “QP-Prostate was designed to seamlessly combine into radiology workflows and ship actual scientific worth. This chance will permit us to show how AI can improve diagnostic confidence, cut back variability, and assist extra equitable entry to high-quality prostate most cancers care.”
The initiative is facilitated by the Small Enterprise Analysis Initiative (SBRI), which helps the NHS in adopting modern applied sciences. The work is commissioned and funded by the NHS Most cancers Programme, with further assist from SBRI Healthcare and the Accelerated Entry Collaborative.
An AI software for prostate most cancers analysis was trialled at Leeds Educating Hospitals NHS Belief in August 2024. The one-month trial was to find out the effectiveness of the Prostate Intelligence (Pi) software from Lucida Medical.
